Clinical Trial Update: A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating Pasritamig (JNJ-78278343) in combination with other agents for metastatic prostate cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Pasritamig

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer | Phase 1 | Status: RECRUITING